Mesoblast Reports Financial Results and Operational

Durable long-term survival outcomes through 4 years for children with steroid-refractory graft versus host disease (SR-aGVHD) treated with remestemcel-L ...

Related Keywords

,Silviu Itescu ,Nasdaq ,Mesoblast Limited ,Chief Executive ,Australian Stock Exchange Msb Ax ,